New transplant prep aims to boost survival in leukemia patients

NCT ID NCT07214064

Not yet recruiting Disease control Sponsor: University Hospital Tuebingen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding venetoclax to standard chemotherapy before a stem cell transplant can improve survival for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study will enroll 27 adults aged 18 to 75. The main goal is to see if the new combination is safe and feasible, measuring survival at 28 days after transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax (Venclyxto®) combined with fludarabine and treosulfan
What this could lead to: If successful, this could offer a safer, more effective transplant preparation for older or frail patients with AML or MDS, potentially improving survival.
What could go wrong: This is a small, early-phase trial with only 27 participants. The added drug may increase side effects without clear benefit, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome myelodysplastic syndrome with excess blasts

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML (ACUTE MYELOID LEUKEMIA) MDS (MYELODYSPLASTIC SYNDROME) MDS/AML

Contacts and locations

Locations

University Hospital , Department of Internal Medicine II

Tübingen, Baden-Wurttemberg, 72076, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.